Beta-lactam antibiotics: is continuous infusion the preferred method of administration?
- PMID: 7633021
- DOI: 10.1177/106002809502900413
Beta-lactam antibiotics: is continuous infusion the preferred method of administration?
Abstract
Objective: To examine the pharmacodynamic properties of the beta-lactam class of antibiotics and the rationale for their continuous infusion (CI), and to explore reasons that this mode of administration has not replaced intermittent infusion as the standard of practice.
Data sources: A Medline search of the English-language literature evaluating CI administration of beta-lactam antibiotics was conducted. Bibliographic searches of these articles also were performed.
Study selection: Because there were few human trials, all available trials were considered for review. A cross section of clinical trials, animal studies, and in vitro studies examining the impact of the route of antibiotic administration was selected for each pharmacodynamic variable addressed.
Data synthesis: The support for CI as the preferred method of beta-lactam administration comes primarily from in vitro and animal data. Most beta-lactam antibiotics do not demonstrate concentration-dependent killing and have an appreciable postantibiotic effect only against gram-positive cocci. Their efficacy appears to be optimized by maintaining suprainhibitory concentrations throughout the dosing interval. Therefore, CI of beta-lactams could potentially enhance the efficacy of treatment or allow less drug to be used on a daily basis. This has yet to be demonstrated convincingly in human clinical trials. Comparative trials need to continue to explore the impact of the method of administration on patient outcomes such as duration and cost of therapy, as well as morbidity and mortality.
Conclusions: Results of many animal and in vitro studies suggest that CI may be the optimal method of beta-lactam administration. Clinical trials need to further document the impact of the method of beta-lactam administration on the incidence of adverse effects, emergence of bacterial resistance, and patient outcome. Pharmacodynamic studies defining target beta-lactam concentrations, the practicality of CI in patients requiring multiple intravenous fluids and medications, and the pertinence of this issue when beta-lactam antibiotics are used as sole agents or in combination with other antimicrobials require further exploration.
Similar articles
-
Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria.Ann Pharmacother. 2009 Jul;43(7):1324-37. doi: 10.1345/aph.1L638. Epub 2009 Jul 7. Ann Pharmacother. 2009. PMID: 19584386 Free PMC article. Review.
-
Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.Swiss Med Wkly. 2016 Oct 10;146:w14368. doi: 10.4414/smw.2016.14368. eCollection 2016. Swiss Med Wkly. 2016. PMID: 27731492 Review.
-
Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics.Minerva Anestesiol. 2012 Jan;78(1):94-104. Epub 2011 Jul 6. Minerva Anestesiol. 2012. PMID: 21730935 Review.
-
Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.Clin Pharmacokinet. 2020 Oct;59(10):1237-1250. doi: 10.1007/s40262-020-00919-6. Clin Pharmacokinet. 2020. PMID: 32710435
-
The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials.J Antimicrob Chemother. 2006 Apr;57(4):639-47. doi: 10.1093/jac/dkl044. Epub 2006 Feb 24. J Antimicrob Chemother. 2006. PMID: 16501057 Review.
Cited by
-
Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients.Intensive Care Med. 2006 Dec;32(12):2063-6. doi: 10.1007/s00134-006-0421-1. Epub 2006 Oct 24. Intensive Care Med. 2006. PMID: 17061021
-
Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.Br J Clin Pharmacol. 2000 May;49(5):445-52. doi: 10.1046/j.1365-2125.2000.00179.x. Br J Clin Pharmacol. 2000. Corrected and republished in: Br J Clin Pharmacol. 2000 Aug;50(2):184-91. doi: 10.1111/j.1365-2125.2000.00179.x. PMID: 10792202 Free PMC article. Corrected and republished. Clinical Trial.
-
Concentrations of Cefuroxime in Brain Tissue of Neurointensive Care Patients.Antimicrob Agents Chemother. 2018 Jan 25;62(2):e02164-17. doi: 10.1128/AAC.02164-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29203481 Free PMC article.
-
Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients.Antimicrob Agents Chemother. 1998 Jul;42(7):1783-7. doi: 10.1128/AAC.42.7.1783. Antimicrob Agents Chemother. 1998. PMID: 9661021 Free PMC article. Clinical Trial.
-
Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae.Antimicrob Agents Chemother. 2020 Feb 21;64(3):e01751-19. doi: 10.1128/AAC.01751-19. Print 2020 Feb 21. Antimicrob Agents Chemother. 2020. PMID: 31844001 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical